Study S002292

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02172313
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 78
Start: 2014-06
Primary completion: 2014-10
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:semaglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2013-004707-39; OTHER:U1111-1149-8127

Registered primary outcomes

Area under the semaglutide plasma concentration time curve [From time 0 to 24 hours after the 10th daily dose]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011209	Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Overgaard RV, Clinical pharmacokinetics	2021	Other trial	PMID 33969456 DOI	cites ClinicalTrials.gov:NCT02172313; registry reference DERIVED:33969456
R0015802	Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation. Bækdal TA, Diabetes therapy : research, treatment and education of diabetes and related disorders	2021	Randomized trial	PMID 34080123 DOI	cites ClinicalTrials.gov:NCT02172313; registry reference DERIVED:34080123